Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318678 · ClinicalTrials.gov registry record · Phase 1
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
A Phase 1 study of B-ALL and AML/MDS, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 2
- Study locations
NCT04318678 is a Phase 1 study of B-ALL and AML/MDS that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 108 participants, above the 72-participant average among 7 other B-ALL trials with a reported enrollment target (50% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT04318678, a Phase 1 study of B-ALL and AML/MDS, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 2
- Study locations
Study Summary
The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leukemia (ALL) or blastic plasmacytoid dendritic cell neoplasia (BPDCN). The purpose of this study is to find the maximum (highest) dose of CD123-CAR T cells that is safe to give to these patients. This would include studying the side effects of the chemotherapy, as well as the CD123-CAR T-cell product on the recipient's body, disease and overall survival. Primary Objective: * To determine the safety of one intravenous infusion of escalating doses of autologous, CD123-CAR T cells in patients (≤21 years) with recurrent/refractory CD123+ disease (AML/MDS, B-ALL, T-ALL or BPDCN) after lymphodepleting chemotherapy. * To determine the safety of an intravenous infusion of escalating doses of donor derived, CD123-CAR T cells in patients (≤21 years) with recurrent/refractory CD123+ disease (AML/MDS, B-ALL, T-ALL, BPDCN or MPAL) after lymphodepleting chemotherapy. Secondary Objectives \- To evaluate the antileukemia activity of CD123-CAR T cells. Exploratory Objectives * To assess the immunophenotype, clonal structure and endogenous repertoire of CD123-CAR T cells and unmodified T cells * To characterize the cytokine profile in the peripheral blood and CSF after treatment with CD123-CAR T cells * To characterize tumor cells post CD123-CAR T-cell therapy * To compare in vivo properties of donor-derived versus autologous CD123- CAR T cells
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG CD123-CAR T
- DRUG Mesna
- DRUG Rituximab
Study Locations (2)
Tennessee
- St Jude Children's Research Hospital - Memphis
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2030-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04318678
The ClinicalTrials.gov registry entry for NCT04318678 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 7 other B-ALL trials with a reported enrollment target (50% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with B-ALL appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04318678 reports 2 study locations spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT04318678 about?
NCT04318678 is a clinical study titled "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)". The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leukemia (ALL) or blastic plasmacytoid dendritic cell neoplasia (BPDCN). The purpose of this study is to find the maximum (highest) dose of CD1...
What is the current status of trial NCT04318678?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2020-07-29. Estimated completion is 2030-07-29.
What conditions does trial NCT04318678 study?
This clinical trial studies the following conditions: B-ALL, AML/MDS, BPDCN, T-ALL.
What interventions are being tested in trial NCT04318678?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CD123-CAR T (DRUG), Mesna (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT04318678?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04318678 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-ALL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
COMPLETED · Phase 1
-
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
COMPLETED · Phase 1
-
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
RECRUITING · NA
-
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
RECRUITING · Early Phase 1
-
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.